Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Post by stockhunter1on Apr 17, 2021 1:05pm
427 Views
Post# 33017320

From the MD&A Dated Feb 2021

From the MD&A Dated Feb 2021Research and Development Outlook Our R&D program for the 2021 fiscal year is anticipated to include: completion of patient enrollment, continuing to treat patients and obtain additional study data for the US Phase I/II clinical trial of our Cell Pouch System under our US IND at the University of Chicago for T1D patients with severe hypoglycemia in collaboration with JDRF; continuing production of human stem-cell-derived islet cells as a potential unlimited cell supply for ongoing in vivo safety and efficacy studies in preparation for future clinical evaluation within our Cell Pouch for the treatment of T1D; proceeding with a development plan to the clinic for our recently acquired Conformal Coating Technology augmented by the now licensed UMiami technology as a local immune protection technology for human donor islets and stem cell-derived technologies for Sernova’s clinical T1D therapeutics; completing the evaluation of AgeX’s UniverCyte local immune protection technology for our hemophilia and diabetes cell therapy applications; continuing to develop relationships towards potential collaborations with medical device (medtech) companies interested in Sernova’s regenerative medicine approach to the treatment of disease; executing R&D collaborations with pharmaceutical companies in support of a potential licensing arrangement and commercial development partnership of our combined technologies for our diabetes and other programs; and advancing our preclinical development programs towards human clinical evaluation for the treatment of postoperative hypothyroid disease and hemophilia A consisting of Cell Pouch transplanted therapeutic tissue / cells. I am posting this for those that are doing diligence, I suggest if you have questions you call Sernova...opposed to calling me names. Good luck
<< Previous
Bullboard Posts
Next >>